Clinical trial
Progression of Hematopoietic Diseases in Shanghai, China
NCT00365014 · University of Colorado, Denver, Other · Completed
Key facts
| NCT number | NCT00365014 |
|---|---|
| Title | Progression of Hematopoietic Diseases in Shanghai, China |
| Official title | Analysis of Disease Progression for Aplastic Anemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia and Benzene Poisoning in Shanghai, China. |
| Lead sponsor | University of Colorado, Denver, Other |
| Collaborators | Fudan University University of Cincinnati ExxonMobil Biomedical Sciences, Inc. Industry British Petroleum P.L.C. Chevron Corporation ConocoPhillips Exxon Mobil Marathon Ashland Shell Chemicals |
| Status | Completed |
| Study type | Observational |
| Conditions | Hematologic Diseases |
| Enrollment | 10,757 |
| Start date | Aug 1, 2003 |
| Primary completion | Dec 1, 2009 |
| Completion | Dec 1, 2009 |
| First posted | Aug 16, 2006 |
| Last update posted | Jul 23, 2013 |
| Countries | China |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: